Starsource Multi

Which are the latest news on Starsource Multi?

Why is Starsource Multitrade Ltd falling/rising?

As of 05-Sep, Starsource Multitrade Ltd's stock price is 79.66, down 0.88%. The stock has declined significantly year-to-date and over the past year, indicating persistent bearish sentiment and reduced investor participation.

As of 05-Sep, Starsource Multitrade Ltd's stock price is currently at 79.66, reflecting a decrease of 0.71, or 0.88%. The stock has been experiencing a downward trend, as evidenced by its performance over various periods. Year-to-date, the stock has fallen by 30.55%, and over the past year, it has decreased by 33.97%. <BR><BR>Despite a recent trend reversal where the stock gained after three consecutive days of decline, it is still trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This indicates a persistent bearish sentiment among investors. Additionally, there has been a significant drop in investor participation, with delivery volume on September 3 falling by 59.02% compared to the 5-day average. <BR><BR>While the stock outperformed its sector by 0.51% today, the overall negative trends in year-to-date and yearly performance, combined with declining investor interest, suggest that the stock is currently facing downward pressure.

Who are in the management team of Starsource Multi?

The management team of Starsource Multi includes Ashok Somani (Executive Director & CFO), Toby Antony (Independent Director), Shanta Somani (Non-Executive Director), Mathura Prasad Sharma (Independent Director), Bhavin Sheth (Director & CEO), Nandkumar Pareek (Independent Director), and Unnatti Jain (Company Secretary & Compliance Officer).

The management team of Starsource Multi includes the following individuals:<BR><BR>1. Ashok Somani - Executive Director & CFO<BR>2. Toby Antony - Independent Director<BR>3. Shanta Somani - Non-Executive Director<BR>4. Mathura Prasad Sharma - Independent Director<BR>5. Bhavin Sheth - Director & Chief Executive Officer<BR>6. Nandkumar Pareek - Independent Director<BR>7. Unnatti Jain - Company Secretary & Compliance Officer<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

What does Starsource Multi do?

Starsource Multitrade Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, reporting no sales or profits as of June 2026, with a market cap of INR 13 Cr. Established in 1942, it has faced significant changes and currently has a negative return on equity and no dividend yield.

Overview:<BR>Starsource Multitrade Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was established in August 1942 and has undergone significant changes, including the disposal of its previous business due to increased competition. As of the latest quarterly results for June 2026, the company reported no sales or profits.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Jun 2026)<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>Market-cap value: INR 13 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 31<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.01<BR>Return on Equity: -932.56%<BR>Price to Book: 9.94<BR><BR>Contact Details:<BR>Address: 5 Kumud Apartment CHS Ltd, Karnik Road Chikan Ghar Kalyan Thane Maharashtra : 421301<BR>Tel: 91-022-22078381/22078382<BR>Email: chemopharmalab@gmail.com<BR>Website: http://www.thechemopharmalaboratoriesltd.com

Who are the peers of the Starsource Multi?

Peers of Starsource Multi include Zenith Health, Desh Rakshak, Dipna Pharmachem, Ortin Global, Unjha Formul., Beryl Drugs, Vivanza Biosci., and Mono Pharmacare. Unjha Formul. has the highest 1-year return at 10.70%, while Dipna Pharmachem has the lowest at -73.42%.

Peers: The peers of Starsource Multi are Zenith Health, Desh Rakshak, Dipna Pharmachem, Ortin Global, Unjha Formul., Beryl Drugs, Vivanza Biosci., and Mono Pharmacare.<BR><BR>Quality Snapshot: Below Average management risk is observed at Zenith Health, Desh Rakshak, Dipna Pharmachem, Ortin Global, Beryl Drugs, Vivanza Biosci., and Mono Pharmacare, while Average management risk is found at Unjha Formul. Excellent growth is noted at Dipna Pharmachem, while Below Average growth is seen at Zenith Health, Desh Rakshak, Ortin Global, and the rest. Good capital structure is present at Zenith Health and Unjha Formul., while Below Average capital structure is found at Desh Rakshak, Dipna Pharmachem, Ortin Global, Beryl Drugs, Vivanza Biosci., and Mono Pharmacare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Unjha Formul. at 10.70%, while Dipna Pharmachem has the lowest at -73.42%. Starsource Multi's 1-year return of -28.59% is better than Dipna Pharmachem's but worse than Unjha Formul.'s. Additionally, Zenith Health, Dipna Pharmachem, and Vivanza Biosci. have negative six-month returns.

How big is Starsource Multi?

As of 31st August, Starsource Multitrade Ltd has a market capitalization of 13.00 Cr, classifying it as a Micro Cap company, with recent net sales of 0.60 Cr and a net loss of 0.04 Cr.

As of 31st August, Starsource Multitrade Ltd has a market capitalization of 13.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 0.60 Cr. However, it experienced a net loss of 0.04 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2016, where the shareholder's funds amounted to 3.67 Cr and total assets were valued at 3.87 Cr.

When is the next results date for Starsource Multitrade Ltd?

The next results date for Starsource Multitrade Ltd is 14 August 2026.

The next results date for Starsource Multitrade Ltd is scheduled for 14 August 2026.

How has been the historical performance of Starsource Multi?

The historical performance of Starsource Multi for the year ending March 2016 was poor, with total operating income of 0.49 Cr, a loss before tax of -1.35 Cr, and a negative EPS of -9.66, indicating significant financial challenges. The company had total liabilities of 3.87 Cr against shareholder's funds of 3.67 Cr, reflecting a precarious financial position.

Answer:<BR>The historical performance of Starsource Multi for the year ending March 2016 shows a challenging financial situation with negative profitability and limited operational activity.<BR><BR>Breakdown:<BR>In March 2016, Starsource Multi reported total operating income of 0.49 Cr, derived primarily from other operating income, as net sales were recorded at 0.00 Cr. The total expenditure, excluding depreciation, amounted to 1.84 Cr, leading to an operating profit (PBDIT) of -1.35 Cr. Consequently, the profit before tax also stood at -1.35 Cr, resulting in a profit after tax of -1.45 Cr. The company had a negative earnings per share (EPS) of -9.66 and an operating profit margin of -273.78%. On the balance sheet, shareholder's funds totaled 3.67 Cr, with total liabilities at 3.87 Cr, indicating a precarious financial position. The cash flow from operating activities was -2.09 Cr, while cash flow from investing activities showed a positive inflow of 2.15 Cr, leading to a net cash inflow of 0.06 Cr by the end of the period, with closing cash and cash equivalents at 0.44 Cr.

Who are the top shareholders of the Chemo Pharma Lab?

The top shareholders of Chemo Pharma Lab are Citric India Ltd with 24.63% and Shree Consultation And Services Pvt Ltd with 3.63%. Individual investors own a combined 65.29%, with no mutual funds or foreign institutional investors currently holding shares.

The top shareholders of Chemo Pharma Lab include Citric India Ltd, which holds the highest promoter stake at 24.63%. Additionally, Shree Consultation And Services Pvt Ltd is the highest public shareholder with a holding of 3.63%. Individual investors collectively own 65.29% of the company. There are no mutual funds or foreign institutional investors currently holding shares in Chemo Pharma Lab.

Is Chemo Pharma Lab overvalued or undervalued?

As of April 25, 2023, Chemo Pharma Lab is considered a risky investment due to its overvaluation indicated by a PE ratio of 19.25, negative EV to EBIT and EBITDA, and a low ROCE of -3.04%, especially when compared to its peers, and it has recently underperformed the market with a one-week return of -9.53%.

As of 25 April 2023, Chemo Pharma Lab's valuation grade has moved from does not qualify to risky, indicating a shift in its perceived investment quality. The company appears to be overvalued based on its current metrics, particularly with a PE ratio of 19.25 and a negative EV to EBIT and EV to EBITDA of -12.50. Additionally, the ROCE stands at -3.04%, which raises concerns about its operational efficiency.<BR><BR>In comparison to its peers, Chemo Pharma Lab's valuation is notably less attractive. For instance, Altius Telecom, categorized as very attractive, has a PE ratio of 52.97, while other peers like Embassy Off.REIT and Inventurus Knowl are deemed very expensive with PE ratios of 23.06 and 56.63, respectively. Chemo Pharma Lab's stock has underperformed recently, with a one-week return of -9.53% compared to a 1.41% gain in the Sensex, further supporting the notion that it is currently overvalued.

What is the technical trend for Chemo Pharma Lab?

As of March 17, 2025, Chemo Pharma Lab's technical trend is bullish, supported by strong upward momentum from the MACD and KST, despite mixed signals from other indicators.

As of 17 March 2025, the technical trend for Chemo Pharma Lab has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting a strong upward momentum. The KST also confirms this bullish stance on both time frames. While the RSI shows no signal, the Bollinger Bands indicate a mildly bullish trend on both weekly and monthly charts. The daily moving averages are mildly bullish, suggesting some short-term strength. Overall, the current technical stance is bullish with a strong momentum indicated by the MACD and KST, despite some mixed signals from other indicators.

Has Chemo Pharma Lab declared dividend?

No Dividend History Available